A Study of HRS7415 Tablets in Patients With Advanced Malignant Tumors

NCT05318833 | Completed Phase 1

• 1 other identifier: HRS7415-I-101
• Study Type: interventional
• Target: 38
• Locations: 1 country
• Sites: 1

Brief Summary

This study is a multicenter, open phase I clinical study of dose escalation and dose extension of HRS7415 in subjects with advanced malignant tumors. To evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS7415 tablets.

Conditions

Advanced Malignant Tumor

Outcome Measures

Primary Outcomes (3)

• Dose-limiting toxicity (DLT)

  From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months

• maximum tolerated dose (MTD)

  From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months

• Phase II recommended dose (RP2D)

  From the beginning of first patient in (FPI) to the end of dose escalation phase up to approximately 10 months

Secondary Outcomes (17)

• Incidence, severity, duration, and association of adverse events (AE) and severe adverse events (SAE) with the study drug, in addition to abnormalities in vital signs, electrocardiogram, and laboratory tests

  From the beginning of first patient in (FPI) to the end of study up to approximately 2 years

• Single dose parameters: Peak plasma concentration (Cmax) of HRS7415 and its main metabolite after single dosing

  From the beginning of first patient in (FPI) to the end of study up to approximately 2 years

• Single dose parameters: Time to peak (Tmax) of HRS7415 and its main metabolite after single dosing

  From the beginning of first patient in (FPI) to the end of study up to approximately 2 year

• Single dose parameters: Area under the curve from 0 to the last measurable concentration time point t (AUC0-t) of HRS7415 and its main metabolite after single dosing (if applicable)

  From the beginning of first patient in (FPI) to the end of study up to approximately 2 years

• Single dose parameters: Area under the time curve from 0 to infinity (AUC0-inf) of HRS7415 and its main metabolite after single dosing (if applicable)

  From the beginning of first patient in (FPI) to the end of study up to approximately 2 years

Study Arms (1)

HRS7415

EXPERIMENTAL

Drug: HRS7415

Interventions

HRS7415 DRUG

Drug: HRS7415

HRS7415

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects volunteered to participate in the clinical study, understood the study procedure and was able to sign informed consent in person.
• to 75 years old, male or female.
• ECOG Performance Status of 0 or 1.
• The estimated survival time is ≥12 weeks.
• Subjects with advanced or metastatic malignancy confirmed by histopathology or cytology.
• Solid tumor subjects had measurable lesions that met RECIST 1.1 criteria.
• Adequate hematology and terminal organ function, with vital organ function meeting the upper and lower limits required by the protocol.
• Male subjects and fertile female subjects must agree to use medically approved contraception during the study period and for 6 months following the study; Fertile female subjects must have a negative serum human chorionic gonadotropin (HCG) test within 7 days prior to initial dosing and must be non-lactation blood pregnancy test must be negative and not lactation.

You may not qualify if:

• Subjects plan to receive any other antitumor therapy during the study period.
• Subjects received chemotherapy, radiotherapy, biotherapy, targeted therapy, or immunotherapy within 4 weeks prior to initial dosing.
• Major surgery other than diagnosis or biopsy was performed within 4 weeks prior to initial dosing.
• Received any other investigational drug or treatment that is not on the market within 4 weeks prior to initial dosing.
• The damage caused by any previous antineoplastic therapy has not recovered to grade ≤1.
• Imaging diagnosis showed tumor lesion or meningeal metastasis in the brain.
• Active heart disease in the 6 months prior to initial dosing.
• Had other malignancies within 5 years prior to first dosing.
• Subjects with poorly controlled hypertension and a previous history of hypertensive crisis or hypertensive encephalopathy.
• Having one of several factors affecting oral medication or having active gastrointestinal disease or other medical conditions that may result in significant influence on drug absorption, distribution, metabolism or excretion;
• Active hepatitis B and C;
• Serious infections that require intravenous antibiotics, antivirals or antifungals to control;
• History of immune deficiency or organ transplantation;
• Comorbidities or any other conditions that, in the investigator's judgment, seriously endanger patient safety or prevent patients from completing the study.

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

Cancer Hospital Affiliated to Shandong First Medical University

Jinan, Shandong, 250021, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: The study was divided into two phases, the dose escalation phase and the dose extension phase of HRS7415 in subjects with advanced malignant tumors.

Study Record Dates

• First Submitted: March 18, 2022
• First Posted: April 8, 2022
• Study Start: May 12, 2022
• Primary Completion: March 20, 2025
• Study Completion: March 20, 2025
• Last Updated: March 13, 2026

Record last verified: 2026-03

Locations

CN (1)